Acquires -Acquired

Thermo Fisher Set to Acquire Molecular Diagnostics Maker Mesa Biotech

January 26, 2021

Thermo Fisher has announced that it has reached a definitive agreement to purchase molecular diagnostics developer Mesa Biotech for approximately $450 million.

The acquisition of the San Diego, Calif., company includes a polymerase chain reaction (PCR)-based rapid test platform that has received Emergency Use Authorization for the SARS-CoV-2 virus and 510(k) marketing clearance for influenza A and B, respiratory syncytial virus (RSV) and Strep A.

The rapid PCR-based test is “highly complementary to our existing offering and will further help us meet the continuing demand for COVID-related testing while we work to rapidly scale and develop point-of care tests for other infectious diseases in the future,” said Mark Stevenson, Thermo Fisher’s chief operating officer. The acquisition is expected to be finalized in the first quarter of 2021.

View today's stories